130 related articles for article (PubMed ID: 29686976)
1. Microsatellite Instability in Mouse Models of Colorectal Cancer.
Currey N; Daniel JJ; Mladenova DN; Dahlstrom JE; Kohonen-Corish MRJ
Can J Gastroenterol Hepatol; 2018; 2018():6152928. PubMed ID: 29686976
[TBL] [Abstract][Full Text] [Related]
2. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon.
Mladenova D; Daniel JJ; Dahlstrom JE; Bean E; Gupta R; Pickford R; Currey N; Musgrove EA; Kohonen-Corish MR
Gut; 2011 Mar; 60(3):350-60. PubMed ID: 20980345
[TBL] [Abstract][Full Text] [Related]
3. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
4. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
[TBL] [Abstract][Full Text] [Related]
5. Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice.
Hu Y; Le Leu RK; Young GP
Int J Cancer; 2005 Oct; 116(6):870-5. PubMed ID: 15849741
[TBL] [Abstract][Full Text] [Related]
6. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
8. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors.
Xicola RM; Llor X; Pons E; Castells A; Alenda C; Piñol V; Andreu M; Castellví-Bel S; Payá A; Jover R; Bessa X; Girós A; Duque JM; Nicolás-Pérez D; Garcia AM; Rigau J; Gassull MA;
J Natl Cancer Inst; 2007 Feb; 99(3):244-52. PubMed ID: 17284719
[TBL] [Abstract][Full Text] [Related]
9. Use of mononucleotide repeat markers for detection of microsatellite instability in mouse tumors.
Bacher JW; Abdel Megid WM; Kent-First MG; Halberg RB
Mol Carcinog; 2005 Dec; 44(4):285-92. PubMed ID: 16240453
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability is infrequent in azoxymethane-induced rat intestinal tumors: An assessment by capillary electrophoresis.
Walchle C; Diwan BA; Shiao YH; Calvert RJ
Toxicol Appl Pharmacol; 1999 May; 157(1):9-15. PubMed ID: 10329502
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.
Mead LJ; Jenkins MA; Young J; Royce SG; Smith L; St John DJ; Macrae F; Giles GG; Hopper JL; Southey MC
Clin Cancer Res; 2007 May; 13(10):2865-9. PubMed ID: 17504984
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model.
Bodo S; Svrcek M; Sourrouille I; Cuillières-Dartigues P; Ledent T; Dumont S; Dinard L; Lafitte P; Capel C; Collura A; Buhard O; Wanherdrick K; Chalastanis A; Penard-Lacronique V; Fabiani B; Fléjou JF; Brousse N; Beaugerie L; Duval A; Muleris M
Oncotarget; 2015 Sep; 6(28):24969-77. PubMed ID: 26327213
[TBL] [Abstract][Full Text] [Related]
13. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability.
Guda K; Upender MB; Belinsky G; Flynn C; Nakanishi M; Marino JN; Ried T; Rosenberg DW
Oncogene; 2004 May; 23(21):3813-21. PubMed ID: 15021908
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression.
Alldinger I; Schaefer KL; Goedde D; Ottaviano L; Dirksen U; Ranft A; Juergens H; Gabbert HE; Knoefel WT; Poremba C
J Cancer Res Clin Oncol; 2007 Oct; 133(10):749-59. PubMed ID: 17530287
[TBL] [Abstract][Full Text] [Related]
15. Linking arsenite- and cadmium-generated oxidative stress to microsatellite instability in vitro and in vivo.
Wu CL; Huang LY; Chang CL
Free Radic Biol Med; 2017 Nov; 112():12-23. PubMed ID: 28690196
[TBL] [Abstract][Full Text] [Related]
16. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
17. Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma.
Saetta AA; Aroni K; Stamatelli A; Lazaris AC; Patsouris E
Arch Dermatol Res; 2005 Sep; 297(3):99-107. PubMed ID: 16012876
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
19. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion.
Samaha HS; Kelloff GJ; Steele V; Rao CV; Reddy BS
Cancer Res; 1997 Apr; 57(7):1301-5. PubMed ID: 9102217
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
